Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 13Fallopian Tube Neoplasms 4Recurrence 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Lung Neoplasms 2Carcinoma 2Breast Neoplasms 2Advanced Endometrial Cancer 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sarcoma, Endometrial Stromal 1Platinum-resistant Recurrent Ovarian Cancer 1Pelvic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 3lenvatinib 2Injections 2anlotinib 1Paclitaxel 1NVP-BKM120 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Injections × Gynecologic × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡